Prognostic value of two-dimensional echocardiography and N-terminal proatrial natriuretic peptide following an acute myocardial infarction -: Assessment of baseline values (2-7 days) and changes at 3 months in patients with a preserved systolic function

被引:35
作者
Otterstad, JE [1 ]
Sutton, MGS
Froeland, GS
Holme, I
Skjærpe, T
Hall, C
机构
[1] Vestfold Cent Hosp, Div Cardiol, N-3116 Tonsberg, Norway
[2] Hosp Univ Penn, Div Cardiovasc, Philadelphia, PA 19104 USA
[3] Ulleval Hosp, Inst Med Stat, Oslo, Norway
[4] Univ Trondheim Hosp, Div Cardiol, Trondheim, Norway
[5] Univ Oslo, Internal Med Res Inst, Oslo, Norway
关键词
myocardial infarction; left ventricular remodelling; N-terminal proatrial natriuretic factor; two-dimensional echocardiography;
D O I
10.1053/euhj.2001.2969
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims The purpose of this prospective, observational study was to evaluate the relationship of left ventricular volumes, systolic function and plasma N-terminal proatrial natriuretic peptide (Nt-proANP) to cardiac morbidity and mortality in post-myocardial infarction patients with left ventricular ejection fraction >40%. Methods and Results Two-dimensional echocardiographic recordings and Nt-proANP measurements were obtained in 834 patients who survived acute myocardial infarction. Patients were examined at 2-7 days and 3 months after the index infarction and followed up for 24 months. All measurements of left ventricular volumes, ejection fraction and Nt-proANP were performed in core laboratories. During follow-up 102 patients sustained one or more incidents of the combined primary end-point: cardiac death (n=11), recurrent infarction (n=55) or heart failure requiring hospitalization or treatment with an ACE inhibitor and a diuretic (n=52). Using Cox proportional hazards model, baseline Nt-proANP predicted these events (chi-square 25-3, P<0.0001), while baseline echo volumes and ejection fraction did not. During the subsequent 3-24 month period, 51 patients suffered a primary end-point: cardiac death (n=9), recurrent infarction (n=29), heart failure (n=21). An increase in left ventricular end-systolic volume was the strongest predictor for adverse events (chi-square 19.1, P<0.0001), especially for heart failure. Individual changes in Nt-proANP did not predict cardiac events, whereas both echocardiographic variables and Nt-proANP measured at 3 months had a prognostic impact on subsequent cardiac events (3-24 months). Conclusions In post-myocardial infarction patients with preserved left ventricular function (left ventricular ejection fraction greater than or equal to40%) baseline Nt-proANP, but not echocardiographic left ventricular volumes predicted adverse cardiac events. Early changes in left ventricular volumes and ejection fraction from baseline to 3 months had a further prognostic impact on subsequent events (3-24 months). (C) 2002 The European Society of Cardiology. Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1011 / 1020
页数:10
相关论文
共 20 条
[1]  
DEVITA C, 1994, LANCET, V343, P1115
[2]   LATE EFFECTS OF ACUTE INFARCT DILATION ON HEART SIZE - A 2 DIMENSIONAL ECHOCARDIOGRAPHIC STUDY [J].
ERLEBACHER, JA ;
WEISS, JL ;
EATON, LW ;
KALLMAN, C ;
WEISFELDT, ML ;
BULKLEY, BH .
AMERICAN JOURNAL OF CARDIOLOGY, 1982, 49 (05) :1120-1126
[3]   ASSESSMENT OF LEFT-VENTRICULAR EJECTION FRACTION AND VOLUMES BY REAL-TIME, 2-DIMENSIONAL ECHOCARDIOGRAPHY - COMPARISON OF CINEANGIOGRAPHIC AND RADIONUCLIDE TECHNIQUES [J].
FOLLAND, ED ;
PARISI, AF ;
MOYNIHAN, PF ;
JONES, DR ;
FELDMAN, CL ;
TOW, DE .
CIRCULATION, 1979, 60 (04) :760-766
[4]  
GLANUZZI P, 2001, AM HEART J, V141, P131
[5]   N-TERMINAL PROATRIAL NATRIURETIC FACTOR - AN INDEPENDENT PREDICTOR OF LONG-TERM PROGNOSIS AFTER MYOCARDIAL-INFARCTION [J].
HALL, C ;
ROULEAU, JL ;
MOYE, L ;
DECHAMPLAIN, J ;
BICHET, D ;
KLEIN, M ;
SUSSEX, B ;
PACKER, M ;
ROULEAU, J ;
ARNOLD, MO ;
LAMAS, GA ;
SESTIER, F ;
GOTTLIEB, SS ;
WUN, CCC ;
PFEFFER, MA .
CIRCULATION, 1994, 89 (05) :1934-1942
[6]  
*HEART OUTC PREV E, 2000, NEW ENGL J MED, V342, P143
[7]  
HOLE T, 2000, EUR J ECHOCARDIOG S2, V1, pS20
[8]  
Otterstad JE, 1997, EUR HEART J, V18, P507
[9]  
Otterstad JE, 1999, SCAND CARDIOVASC J, V33, P234
[10]   The HOPE study: Comparison with other trials of secondary prevention [J].
Otterstad, JE ;
Sleight, P .
EUROPEAN HEART JOURNAL, 2001, 22 (15) :1307-1310